Baygam Market Report 2026

Baygam Market Overview

• The Baygam market growth in the historic period has been driven by high rabies mortality rates, reliance on immunoglobulin therapy • Market expansion is supported by increasing animal bite incidents, expansion of vaccination programs • Growth Driver: Rising Prevalence Of Immunodeficiency Diseases To Drive Baygam Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Baygam Market?

Baygam refers to human rabies immunoglobulin (HRIG) used in post-exposure prophylaxis (PEP) for individuals potentially exposed to the rabies virus. It is typically administered along with the rabies vaccine to provide immediate passive immunity while the body generates its own active immune response through vaccination. The main types of indications in baygam are primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barré syndrome. Primary immunodeficiency refers to a group of disorders where the immune system is not functioning properly from birth, leading to increased susceptibility to infections. It is distributed through hospitals, clinics, and home care for various end users, including adults, geriatrics, and pediatrics.

What Is The Baygam Market Growth Forecast?

The growth in the forecast period can be attributed to increasing animal bite incidents, expansion of vaccination programs, rising healthcare access in developing regions, improved cold chain distribution, government supported rabies control initiatives. Major trends in the forecast period include rising demand for post exposure prophylaxis, expansion of rabies prevention programs, increased use of passive immunization therapies, growing hospital and clinic administration of hrig, strengthening of emergency infectious disease care.

Global Baygam Market Segmentation

1) By Indication: Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome 2) By Distribution Channel: Hospitals, Clinics, Homecare 3) By End User: Adult, Geriatric, Pediatric

What Are The Drivers Of The Baygam Market?

Increasing prevalence of immunodeficiency diseases is expected to propel the growth of the baygam market going forward. Immunodeficiency diseases refer to disorders where the immune system is either absent or weakened, reducing its ability to fight infections and other diseases. The rising prevalence of immunodeficiency diseases is driven by improved diagnosis and awareness, alongside an aging population with weakened immune systems, increasing susceptibility to infections and immune disorders. Baygam helps patients with immunodeficiency diseases by providing intravenous immunoglobulin (IVIG) therapy, which replenishes essential antibodies in the body, thereby boosting the immune system’s ability to fight infections and reduce the frequency and severity of bacterial and viral infections in individuals with weakened immune responses. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 HIV diagnoses in England (including individuals previously diagnosed abroad) in 2023, marking a 51% rise from 3,975 cases reported in 2022. Therefore, the rising prevalence of immunodeficiency diseases is contributing to the growth of the baygam industry. The rising healthcare expenditure is expected to propel the growth of the baygam market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure supports baygam utilization by improving access to essential immunoglobulin therapies and strengthening overall healthcare infrastructure. It enables timely treatment for immune deficiencies and exposure-related conditions, enhancing patient outcomes and preventive care. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the baygam industry.

Key Players In The Global Baygam Market

Major companies operating in the baygam market are Grifols S.A

What Are Latest Mergers And Acquisitions In The Baygam Market?

In March 2023, Selagine, Inc., a US-based company focused on developing novel therapeutics, partnered with Grifols S.A. This collaboration aims to develop innovative immunoglobulin eye drops for treating dry eye disease (DED), leveraging Grifols' expertise in plasma-derived therapies and Selagine's ocular treatment research to address a significant unmet medical need affecting over 100 million people worldwide. Grifols S.A. is a Spain-based pharmaceutical company that specializes in developing and producing plasma-derived medicines, including various types of immune globulins.

Regional Insights

North America was the largest region in the baygam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Baygam Market?

The baygam market consists of sales of products including imogam, hyperrab, kedrab, rabishield, and bayrab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Baygam Market Report 2026?

The baygam market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the baygam industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.